Cleaning validation remains a cornerstone of pharmaceutical quality assurance, ensuring that manufacturing equipment is consistently cleaned to predetermined acceptance criteria that protect patient safety and product quality. The pharmaceutical industry has witnessed a significant paradigm shift from traditional compliance-based approaches toward science-based, risk-based methodologies for cleaning validation. This paper provides a comprehensive review of risk-based cleaning validation, examining the regulatory framework established by ICH Q9 and related guidelines, the evolution of acceptance criteria from arbitrary limits to health-based exposure limits, and the application of quality risk management tools such as Failure Mode and Effects Analysis. The lifecycle approach to cleaning validation, sampling methodologies, and strategies for preventing cross-contamination in multi-product facilities are discussed. This review synthesizes current literature and regulatory expectations to provide pharmaceutical professionals with practical guidance for implementing robust, scientifically justified cleaning validation programs.
Background: Cleaning validation is a critical component of pharmaceutical manufacturing quality assurance, ensuring the prevention of cross-contamination between production batches. Two predominant analytical techniques, High-Performance Liquid Chromatography (HPLC) and Total Organic Carbon (TOC) analysis, are widely employed for residue detection, yet the optimal selection between these methodologies remains a subject of ongoing debate within the industry. Objective: This review critically evaluates the comparative advantages, limitations, and application contexts of HPLC and TOC analysis in pharmaceutical cleaning validation programs, providing evidence-based guidance for method selection. Methods: A comprehensive literature review was conducted examining peer-reviewed publications, regulatory guidance documents, and industry case studies from 2010 to 2025. Selection criteria included studies comparing analytical performance, regulatory compliance, and practical implementation considerations. Results: HPLC demonstrates superior specificity for active pharmaceutical ingredient (API) quantification with detection limits typically ranging from 0.1–10 µg/mL, while TOC analysis offers advantages in non-specific organic contamination detection with broader applicability and faster analysis times (typically 3–8 minutes versus 15–60 minutes for HPLC). Regulatory guidance from the FDA and EMA supports both methodologies when appropriately validated, with the selection dependent on the specific cleaning validation objectives. Conclusions: Neither technique is universally superior; rather, the optimal choice depends on the validation objective, equipment characteristics, product portfolio complexity, and regulatory requirements. A risk-based approach combining both methodologies may provide the most comprehensive cleaning validation strategy for multi-product facilities.